DC-DORSEY-&-WHITNEY-LLP
2.11.2020 18:26:12 CET | Business Wire | Press release
International law firm Dorsey & Whitney LLP announced today that former senior CFIUS official Justin Huff has joined the Firm as a Partner in its Washington D.C. office.
Before entering private practice, Mr. Huff served as a Deputy Director in the United States Department of the Treasury office responsible for chairing the Committee on Foreign Investment in the United States (CFIUS), an interagency committee that reviews cross-border mergers, acquisitions and certain investment transactions for potential national security concerns. Mr. Huff led the review of hundreds of CFIUS filings and conducted in-depth national security analyses on transactions across a wide range of industries, including biotech, agriculture, technology, telecommunication, real estate, energy, and others. Mr. Huff also engaged in extensive inter-agency communications and consensus building with the eight other agencies on the CFIUS committee.
Before his Treasury position, Mr. Huff served as a senior intelligence analyst for the Office of Homeland Security and Emergency Coordination at the U.S. Department of Agriculture, where he managed departmental requirements and briefed White House officials and other federal agencies. He also was a senior intelligence advisor at the Office of the Director of National Intelligence, where he worked across federal departments and agencies to rally interagency support for initiatives that enhanced intelligence and information sharing between federal departments and the intelligence community.
After serving in the federal government as a national security official for over a decade, Mr. Huff entered the private law practice at another international law firm. Mr. Huff guided domestic and international clients on CFIUS regulations and their impact on hundreds of high-profile cross-border corporate transactions. Clients praise Mr. Huff for his deep knowledge of the CFIUS regulations and process, and for his ability to find practical and business-sensitive solutions, whether for a pending transaction or in connection with a post-closing CFIUS investigation or review.
Mr. Huff joins an experienced team of Dorsey attorneys who have filed and handled CFIUS notices and investigations on behalf of domestic and international clients in cross-border M&A and investment transactions since 1988. The lawyers at Dorsey have appeared for various clients before CFIUS and, through that extensive experience, have developed excellent, close, and mutually respectful relationships with CFIUS management and staff, including, where appropriate, the ability to meet directly with those officials in Washington, DC.
“With his experience as a senior CFIUS officer, Justin is knowledgeable not only about CFIUS regulations but also about the internal CFIUS processes and practice,” said Dorsey managing partner Bill Stoeri. “In light of the significant changes in CFIUS regulations, including the adoption of the Foreign Investment Risk Review Modernization Act of 2018 (FIRRMA), the expansion of CFIUS jurisdiction, the mandatory filing requirements and expansion of CFIUS’s operations and enforcement, Justin’s expertise and experience will help Dorsey clients with the growing regulatory demands placed on cross-border transactions.”
About Dorsey & Whitney LLP
Clients have relied on Dorsey since 1912 as a valued business partner. With locations across the United States and in Canada, Europe and the Asia-Pacific region, Dorsey provides an integrated, proactive approach to its clients' legal and business needs. Dorsey represents a number of the world's most successful companies from a wide range of industries, including leaders in banking & financial institutions, development & infrastructure, energy & natural resources, food, beverage & agribusiness, healthcare and technology, as well as major non-profit and government entities. www.dorsey.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005791/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
